Nature Communications (Dec 2016)
Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment
- Jin Yang,
- Konstantinos Savvatis,
- Jong Seok Kang,
- Peidong Fan,
- Hongyan Zhong,
- Karen Schwartz,
- Vivian Barry,
- Amanda Mikels-Vigdal,
- Serge Karpinski,
- Dmytro Kornyeyev,
- Joanne Adamkewicz,
- Xuhui Feng,
- Qiong Zhou,
- Ching Shang,
- Praveen Kumar,
- Dillon Phan,
- Mario Kasner,
- Begoña López,
- Javier Diez,
- Keith C. Wright,
- Roxanne L. Kovacs,
- Peng-Sheng Chen,
- Thomas Quertermous,
- Victoria Smith,
- Lina Yao,
- Carsten Tschöpe,
- Ching-Pin Chang
Affiliations
- Jin Yang
- Krannert Institute of Cardiology and Division of Cardiology, Department of Medicine, Indiana University School of Medicine
- Konstantinos Savvatis
- Department of Cardiology, Campus Virchow-Klinikum, Charité University Medicine Berlin
- Jong Seok Kang
- Gilead Sciences Inc.
- Peidong Fan
- Gilead Sciences Inc.
- Hongyan Zhong
- Gilead Sciences Inc.
- Karen Schwartz
- Gilead Sciences Inc.
- Vivian Barry
- Gilead Sciences Inc.
- Amanda Mikels-Vigdal
- Gilead Sciences Inc.
- Serge Karpinski
- Gilead Sciences Inc.
- Dmytro Kornyeyev
- Gilead Sciences Inc.
- Joanne Adamkewicz
- Gilead Sciences Inc.
- Xuhui Feng
- Krannert Institute of Cardiology and Division of Cardiology, Department of Medicine, Indiana University School of Medicine
- Qiong Zhou
- Krannert Institute of Cardiology and Division of Cardiology, Department of Medicine, Indiana University School of Medicine
- Ching Shang
- Krannert Institute of Cardiology and Division of Cardiology, Department of Medicine, Indiana University School of Medicine
- Praveen Kumar
- Gilead Sciences Inc.
- Dillon Phan
- Gilead Sciences Inc.
- Mario Kasner
- Department of Cardiology, Campus Virchow-Klinikum, Charité University Medicine Berlin
- Begoña López
- Department of Cardiology and Cardiac Surgery, Program of Cardiovascular Diseases, Centre for Applied Medical Research, University Clinic, University of Navarra
- Javier Diez
- Department of Cardiology and Cardiac Surgery, Program of Cardiovascular Diseases, Centre for Applied Medical Research, University Clinic, University of Navarra
- Keith C. Wright
- Krannert Institute of Cardiology and Division of Cardiology, Department of Medicine, Indiana University School of Medicine
- Roxanne L. Kovacs
- Krannert Institute of Cardiology and Division of Cardiology, Department of Medicine, Indiana University School of Medicine
- Peng-Sheng Chen
- Krannert Institute of Cardiology and Division of Cardiology, Department of Medicine, Indiana University School of Medicine
- Thomas Quertermous
- Division of Cardiovascular Medicine, Stanford University
- Victoria Smith
- Gilead Sciences Inc.
- Lina Yao
- Gilead Sciences Inc.
- Carsten Tschöpe
- Department of Cardiology, Campus Virchow-Klinikum, Charité University Medicine Berlin
- Ching-Pin Chang
- Krannert Institute of Cardiology and Division of Cardiology, Department of Medicine, Indiana University School of Medicine
- DOI
- https://doi.org/10.1038/ncomms13710
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 15
Abstract
Lysyl oxidase-like 2 (LOXL2) is an enzyme that promotes scaffolding of extracellular matrix proteins. Here the authors show that LOXL2 is crucial for pressure-overload induced cardiac fibrosis, and that antibody-mediated inhibition or genetic disruption ofLoxl2in mice shows therapeutic potential for treatment of cardiac fibrosis.
